A Study of Characterizing Cognitive Decline and Functional Cardiac Senescence in Healthy Korean Volunteers

NCT ID: NCT01590706

Last Updated: 2014-04-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

116 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-11-30

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Although aging process appears to be generally characterized, investigators have been paid much attention to the specific target molecules, which leads to discover the clinical markers of the senescence. The present study is to investigate the clinical and biological profile of cognitive decline and functional cardiac senescence in healthy middle aged and elderly Korean volunteers.
* This study was conducted as a cross-sectional, single-center, comparative clinical study.
* Each volunteer was given informed consent for checking cognition and cardiac function. Blood and urine samples were collected to analyze genome, proteome, and metabolome to assess cognition and cardiac function of its muscle enzymes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* The protocol of this study was developed as the first assessment of the three to four series of clinical research on senescence.
* This design of the study is a non-interventional, single-center, single-visit design for investigating the cognitive decline and cardiac function including heart muscle enzyme activity, which have been considered one of the key points in aging process.
* Volunteers visit the study site during the screening period, informed consent for study participation and blood draw are given respectively, then, the eligibilities are met, participants visit the study site just once within two weeks.
* The participants undergo the following five procedures for 2-3 hours; out-patient visit,

1. additional demographic interview including covariate factors (depression status, marital status
2. vital sign check
3. the questionnaire for cognitive function
4. blood draw for genomic, proteomic, and metabolomic analyses (10 milli Liter), urine collection (20 milli Liter)
5. electrocardiogram (ECG), then they are discharged.
* Their safety follow-up is monitored in a week (± 1 day) by a phone-call from the study associates.
* To evaluate cognitive function, several cognitive batteries were used, 3MSE (Modified-Mini Mental State Examination), ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale); for cognitive biomarkers, Apolipoprotein E, Type-3 metabotropic glutamate receptors.
* To evaluate cardiac function including its enzyme activity: HRV (heart rate variability), CRP (c-reactive protein); Cardiac Troponin T.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging Mild Cognitive Impairment Angina Pectoris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subjects \>= 45 and \<= 80 years of age
* who understands the study procedures signs informed consent forms

Exclusion Criteria

* who \> 150 mmHg in systolic or \< 95 mmHg in diastolic blood pressure
* who \> 110 mg/dl in fast glucose level
* Smoking \> 20 cigarettes/day
* Alcohol \> 3 units/day (1 unit = pure alcohol 10 milli Liter)
* Caffeine \> 5 cups of coffee or tea/day
Minimum Eligible Age

45 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Daejeon University

OTHER

Sponsor Role collaborator

Korea Institute of Oriental Medicine

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dal-Seok Oh, OMD, PhD

Senior Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Miyoung Lee, PhD

Role: STUDY_DIRECTOR

Korea Institute of Oriental Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dunsan Oriental Hospital of Daejeon Univ.

Daejeon, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KC1101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

China Cognition and Aging Study
NCT03653156 RECRUITING
Cohort Study on Cognitive Decline in Elderly
NCT07093892 NOT_YET_RECRUITING
Cognitive Decline in AD
NCT03946930 RECRUITING
China Healthy Aging Cohort Study
NCT06472674 RECRUITING